BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...BioCentury Staff Bristol Myers Squibb Co. Regeneron Pharmaceuticals Inc. Sanofi La Jolla Pharmaceutical Co. Shionogi & Co. Ltd. Tetra Therapeutics Alnylam Pharmaceuticals Inc. Hydroxyacid oxidase 1 (HAO1) Interleukin-4...
BioCentury | Jan 16, 2019
Distillery Therapeutics


...could include testing the long-term safety of the HAO1-targeting gene therapies in animal models. TARGET/MARKER/PATHWAY: Hydroxyacid oxidase 1 (HAO1)...
...Rodriguez-Madoz, same affiliation as above email: Sandi Wong University of La Laguna University of Navarra Alanine-glyoxylate aminotransferase (AGXT) Glycolate oxidase Hydroxyacid oxidase 1 (HAO1) Hyperoxaluria...
BioCentury | Feb 28, 2018
Distillery Techniques

Drug platforms

...conjugated to hepatocyte-targeting N-acetylgalactosamine (GalNAc) to form a duplex. In rats, an siRNA duplex targeting hydroxyacid oxidase 1 (HAO1)...
BioCentury | May 23, 2016
Clinical News

DCR-PH1: Phase I started

...Molecular target: Hydroxyacid oxidase 1 (HAO1) mRNA Description: Dicer substrate short interfering RNA (siRNA) targeting mRNA carrying the hydroxyacid oxidase 1 (HAO1)...
BioCentury | Jan 5, 2015
Company News

Tekmira, Dicerna deal

Tekmira granted Dicerna worldwide rights to lipid nanoparticle (LNP) technology to deliver Dicerna’s DCR-PH1 . The product is a dicer substrate short interfering RNA targeting mRNA encoded by the hydroxyacid oxidase 1 ( HAO1 ) gene in preclinical...
Items per page:
1 - 5 of 5